Chief Development Officer

Dr. Judith Boice joined Tremeau in 2019 as Chief Development Officer. Dr. Boice has more than 30 years of pharmaceutical industry experience.

Prior to joining Tremeau, she was Vice President and Global Development Team Leader responsible for the Transplant and Atypical Hemolytic Uremic Syndrome programs, as well as Medical Communications Head at Alexion Pharmaceuticals.

Prior to Alexion, Dr. Boice spent 16 years at Merck Research Laboratories. She joined Merck as a senior research biochemist, but spent the bulk of her career there in Clinical Immunology. During her time at Merck she was responsible for executive oversight for numerous clinical trials for the COX-2 inhibitors Vioxx and Arcoxia including perioperative pain, acute gouty arthritis, rheumatoid arthritis, osteoarthritis, and cancer pain. As Executive Director and Senior Project Leader at Merck, Dr. Boice also led development teams focused on numerous early- and late-stage immunology programs including Emend, Remicade, and Simponi. Dr. Boice also briefly served as Vice President, Integrated Drug Development at Covance.

Dr. Boice holds a BS from Cornell University, and a PhD in Biochemistry from University of Connecticut and completed post-doctoral programs at both Fox Chase Cancer Center and Bristol-Myers Squibb.